About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 4565   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size


 
  Table of Contents 
CASE REPORT
Year : 2013  |  Volume : 20  |  Issue : 1  |  Page : 83-86  

Transient increased exudation after photodynamic therapy of intraocular tumors


Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA, USA

Date of Web Publication23-Jan-2013

Correspondence Address:
Arman Mashayekhi
Ocular Oncology Service, Suite 1440, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107
USA
Login to access the Email id

Source of Support: Support provided by a donation from Michael, Bruce, and Ellen Ratner, New York, NY 20 (JAS, CLS), the Paul Kayser International Award of Merit in Retina Research, Houston TX (JAS), Mellon Charitable Giving from the Martha W. Rogers Charitable Trust, Philadelphia, PA (CLS) and the Eye Tumor Research Foundation, Philadelphia, PA (CLS, JAS), Conflict of Interest: None


DOI: 10.4103/0974-9233.106400

Rights and Permissions
   Abstract 

To report transient increased exudation after photodynamic therapy (PDT) of three different intraocular tumors (retinal hemangioblastoma, retinal astrocytoma, amelanotic choroidal melanoma). PDT with verteporfin (6 mg/m [2] body surface area) was delivered at a dose of 50 J/cm [2] and intensity of 600 mW/cm [2] over 83 s. All patients experienced decreased vision within a few days following PDT. Optical coherence tomography showed development of subfoveal fluid in all cases and noncystoid intraretinal edema in the eye with juxtapapillary retinal hemangioblastoma. There was complete absorption of retinal/subretinal fluid with improvement of visual acuity to 20/20 in all cases between 3 weeks to 4 months after PDT.

Keywords: Astrocytoma, Choroidal Melanoma, Complication, Exudation, Eye, Photodynamic Therapy, Retinal Hemangioblastoma, Serous Retinal Detachment, Tumor


How to cite this article:
Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol 2013;20:83-6

How to cite this URL:
Mashayekhi A, Shields CL, Shields JA. Transient increased exudation after photodynamic therapy of intraocular tumors. Middle East Afr J Ophthalmol [serial online] 2013 [cited 2020 Aug 4];20:83-6. Available from: http://www.meajo.org/text.asp?2013/20/1/83/106400


   Introduction Top


Photodynamic therapy (PDT) is based on the interaction of light with a photosensitizer leading to release of cytotoxic singlet oxygen and resultant oxidative damage to the target tissue. [1] The tumoricidal activity of PDT is caused by direct cell damage and microvascular injury. [2],[3],[4] PDT has been used for the management of various intraocular tumors including circumscribed [5],[6],[7],[8] and diffuse choroidal hemangioma, [5],[6],[7],[8],[9] choroidal melanoma, [10],[11],[12] retinal hemangioblastoma, [13],[14],[15],[16] retinal vasoproliferative tumor, [17],[18] and retinal astrocytoma. [19],[20],[21] We describe the development of transient tumor vascular hyperpermeability with increased intraretinal/subretinal fluid following PDT of three different types of intraocular tumors (retinal hemangioblastoma, retinal astrocytoma, amelanotic choroidal melanoma).

Approval was obtained from institutional review board of Wills Eye Institute. Written informed consent was obtained from patients.


   Case Reports Top


Case 1

An asymptomatic 61-year-old female with a 1.5 mm juxtapapillary retinal hemangioblastoma OD showed progressive retinal edema despite three prior off-label intravitreal bevacizumab injections (1.5 mg) [Figure 1]a and b. PDT was delivered to the tumor, followed immediately by a fourth intravitreal bevacizumab injection (1.5 mg). One day after the procedure, the patient presented with a complaint of blurred vision. On examination, the best corrected visual acuity (BCVA) had decreased from 20/20 preoperatively to 20/70. Optical coherence tomography (OCT) showed extension of retinal edema into fovea [Figure 1]c.

There was spontaneous recovery of BCVA to 20/25 and complete resolution of macular edema 3 weeks after PDT [Figure 1]d. Eight months after PDT BCVA was 20/20 but the patient complained of a persistent paracentral ring of haziness. The tumor remained stable with no recurrent intra- or subretinal fluid during subsequent follow-up of 3 years.
Figure 1: (a) Juxtapapillary retinal hemangioblastoma with adjacent lipid exudation. Note minimal lipid exudation in the papillomacular bundle region (b) Foveal contour is normal before photodynamic theraphy (PDT) (c) OCT performed 1 day after PDT shows retinal edema and subretinal fluid under the foveola (d) Three weeks after PDT there is complete reabsorption of intraretinal and subretinal fluid. There are a few focal intraretinal optically dense juxtafoveal deposits consistent with ophthalmoscopically visible lipid exudates

Click here to view


Case 2

A 17-year-old female with juxtafoveal retinal astrocytoma OD measuring 6 mm in diameter and 3 mm in thickness underwent successful standard fluence PDT with verteporfin (6 mg/m [2] ; 689 nm diode laser; 600 mW/cm [2] ; 83 s) for management of macular edema originating from the retinal tumor with improvement in BCVA from 20/70 to 20/30. Three years after PDT, BCVA decreased to 20/60 due to recurrent macular edema [Figure 2]a and b and she underwent a second standard fluence PDT with verteporfin. Two days after the second PDT, she noted decreased vision. On examination, the BCVA was 20/80 and OCT showed increased subretinal fluid at the fovea [Figure 2]c. Three weeks later BCVA improved to 20/60 and 4 months later best corrected visual acuity was 20/20 with complete resolution of macular edema and subfoveal fluid [Figure 2]d. The patient required two more sessions of PDT during the subsequent 3 years for management of recurrent macular edema.
Figure 2: (a) Partially pigmented retinal astrocytoma (needle biopsy proven) with lipid exudation at the superior, inferior, and nasal margins extending into the fovea, forming a foveal star (b) OCT before PDT reveals moderate intraretinal cystoid edema at the fovea (c) Three days after PDT there is increased subretinal fluid (d) Four months later, there is complete reabsorption of intraretinal and subretinal fluid leaving retinal atrophy

Click here to view


Case 3

A 62-year-old female with visual acuity of 20/20 and an enlarging amelanotic choroidal melanoma in her left eye (OS) measuring 7 mm in basal dimension and 2.7 mm in thickness [Figure 3]a and b was treated with PDT. Two days after PDT, the patient noted decreased vision OS and 11 days later, the best corrected visual acuity was measured at 20/200. OCT confirmed subretinal fluid extending from the treated melanoma into the foveal region [Figure 3]c. The vision improved without treatment 1 month after PDTand 3 months later there was complete resolution of subretinal fluid with visual acuity of 20/20 [Figure 3]d. Subsequent tumor growth required treatment with I-125 plaque radiation.
Figure 3: (a) Color fundus photograph showing small amelanotic choroidal melanoma with documented growth (b) OCT shows normal fovea before PDT (c) Eleven days after PDT, neurosensory retinal detachment extending under the fovea is evident (d) Three months after PDT, subretinal fluid has completely disappeared and foveal contour has returned to normal

Click here to view



   Discussion Top


Increased exudation has been reported following PDT of ocular conditions other than tumors, including choroidal neovascular membrane (CNVM) and polypoidal choroidal vasculopathy. [22],[23],[24],[25] Reports of increased leakage after PDT from intraocular tumors are limited to juxtapapillary retinal hemangioblastoma. [13],[16] Possible mechanisms of post-PDT vascular hyper-permeability include direct damage to endothelial cells, [26] retinal pigment epithelial damage and dysfunction, [27],[28] or an angiogenic response induced by PDT. [29],[30]

A post-PDT increase in intraocular tumor leakage is an early phenomenon causing symptoms within a few days of PDT. In all three of our cases, the visual disturbance was transient with complete absorption of fluid and recovery of vision to pre-PDT levels within 1 month after PDT. Despite the transient nature of increased leakage post-PDT, prolonged presence of intraretinal or subretinal fluid or deposition of lipid exudate at the fovea could potentially lead to permanent structural damage and loss of vision. An example is the patient in Case 1 above who noted persistent paracentral field defects up to 8 months after complete absorption of fluid.

The use of off-label intravitreal bevacizumab injection immediately after PDT in our first case did not prevent development of increased retinal edema. It has been shown that increased vascular leakage starts as early as 5-10 min after PDT of rat cremaster muscle. [3] Additionally some have proposed that application of anti-VEGF compounds before PDT may be more effective in blocking the effects of VEGF. [30] Fingar and co-workers [3] also found a direct relationship between dose of photosensitive material used (Photofrin; Pinnacle Biologics Inc., Bannockburn, IL, USA) and the severity of increased vascular leakage and were able to block post-PDT leakage by intra-arterial injection of indomethacin.

In summary, we report development of transient increased leakage causing increased retinal edema or subretinal fluid following PDT for different types of intraocular tumors (retinal hemangioblastoma, retinal astrocytoma, amelanotic choroidal melanoma). Further studies are needed to identify effective methods for prevention of this potentially vision-threatening complication.

 
   References Top

1.Oleinick NL, Evans HH. The photobiology of photodynamic therapy: Cellular targets and mechanisms. Radiat Res 1998;150:S146-56.  Back to cited text no. 1
[PUBMED]    
2.Henderson BW, Fingar VH. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem Photobiol 1989;49:299-304.  Back to cited text no. 2
[PUBMED]    
3.Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: The effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 1992;52:4914-21.  Back to cited text no. 3
[PUBMED]    
4.Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-8.  Back to cited text no. 4
[PUBMED]    
5.Schmidt-Erfurth UM, Michels S, Kusserow C, Jurklies B, Augustin AJ. Photodynamic therapy for symptomatic choroidal hemangioma: Visual and anatomic results. Ophthalmology 2002;109:2284-94.  Back to cited text no. 5
[PUBMED]    
6.Landau IM, Steen B, Seregard S. Photodynamic therapy for circumscribed choroidal haemangioma. Acta Ophthalmol Scand 2002;80:531-6.  Back to cited text no. 6
[PUBMED]    
7.Singh AD, Kaiser PK, Sears JE, Gupta M, Rundle PA, Rennie IG. Photodynamic therapy of circumscribed choroidal haemangioma. Br J Ophthalmol 2004;88:1414-8.  Back to cited text no. 7
[PUBMED]    
8.Boixadera A, García-Arumí J, Martínez-Castillo V, Encinas JL, Elizalde J, Blanco-Mateos G, et al. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009;116:100-5.  Back to cited text no. 8
    
9.Huiskamp EA, Müskens RP, Ballast A, Hooymans JM. Diffuse choroidal haemangioma in sturge-weber syndrome treated with photodynamic therapy under general anaesthesia. Graefes Arch Clin Exp Ophthalmol 2005;243:727-30.  Back to cited text no. 9
    
10.Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LH. Photodynamic therapy of pigmented choroidal melanomas. Invest Ophthalmol Vis Sci 1995;36:871-8.  Back to cited text no. 10
[PUBMED]    
11.Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898-9.  Back to cited text no. 11
[PUBMED]    
12.Donaldson MJ, Lim L, Harper CA, Mackenzie J, G Campbell W. Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin Experiment Ophthalmol 2005;33:548-9.  Back to cited text no. 12
[PUBMED]    
13.Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002;109:1256-66.  Back to cited text no. 13
[PUBMED]    
14.Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R. Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch Ophthalmol 2005;123:328-32.  Back to cited text no. 14
[PUBMED]    
15.Ziemssen F, Voelker M, Inhoffen W, Bartz-Schmidt KU, Gelisken F. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond) 2007;21:1125-6.  Back to cited text no. 15
[PUBMED]    
16.Mennel S, Meyer CH, Callizo J. Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol 2009 [Epub ahead of print].  Back to cited text no. 16
    
17.Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E. Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006;26:404-9.  Back to cited text no. 17
[PUBMED]    
18.Saldanha MJ, Edrich C. Treatment of vasoproliferative tumors with photodynamic therapy. Ophthalmic Surg Lasers Imaging 2008;39:143-5.  Back to cited text no. 18
[PUBMED]    
19.Mennel S, Hausmann N, Meyer CH, Peter S. Photodynamic therapy for exudative hamartoma in tuberous sclerosis. Arch Ophthalmol 2006;124:597-9.  Back to cited text no. 19
[PUBMED]    
20.Shields CL, Materin MA, Marr BP, Krepostman J, Shields JA. Resolution of exudative retinal detachment from retinal astrocytoma following photodynamic therapy. Arch Ophthalmol 2008;126:273-4.  Back to cited text no. 20
[PUBMED]    
21.Eskelin S, Tommila P, Palosaari T, Kivelä T. Photodynamic therapy with verteporfin to induce regression of aggressive retinal astrocytomas. Acta Ophthalmol 2008;86:794-9.  Back to cited text no. 21
    
22.Holz ER, Linares L, Mieler WF, Weinberg DV. Exudative complications after photodynamic therapy. Arch Ophthalmol 2003;121:1649-52.  Back to cited text no. 22
[PUBMED]    
23.Mennel S, Meyer CH, Eggarter F, Peter S. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am J Ophthalmol 2005;140:758-60.  Back to cited text no. 23
[PUBMED]    
24.Jalil A, Mercieca K, Chaudhry NL, Stanga PE. Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: An OCT and FFA study. Eur J Ophthalmol 2009;19:490-3.  Back to cited text no. 24
[PUBMED]    
25.Tobita H, Ohno-Matsui K, Ogawa M, Kaneko Y, Shimada N, Mochizuki M. Transient serous retinal detachment after photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2008;52:518-20.  Back to cited text no. 25
[PUBMED]    
26.Schmidt-Erfurth U, Laqua H, Schlötzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-44.  Back to cited text no. 26
    
27.Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994;101:1953-61.  Back to cited text no. 27
[PUBMED]    
28.Schnurrbusch UE, Welt K, Horn LC, Wiedemann P, Wolf S. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001;85:1086-91.  Back to cited text no. 28
[PUBMED]    
29.Ferrario A, Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 2006;25:251-9.  Back to cited text no. 29
[PUBMED]    
30.Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44:4473-80.  Back to cited text no. 30
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]


This article has been cited by
1 Clinical use of photodynamic therapy in ocular tumors
Eren Cerman,Osman Çekiç
Survey of Ophthalmology. 2015; 60(6): 557
[Pubmed] | [DOI]
2 Authoræs response: Ocular photodynamic therapy with verteporfin in pigmented and amelanotic choroidal melanoma
Eren Cerman,Osman Çekiç
Survey of Ophthalmology. 2015; 60(6): 600
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
   Case Reports
   Discussion
    References
    Article Figures

 Article Access Statistics
    Viewed2301    
    Printed73    
    Emailed0    
    PDF Downloaded103    
    Comments [Add]    
    Cited by others 2    

Recommend this journal